A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: Implications and management for clinical practice

R. Douglas Bruce, David E. Moody, Frederick L. Altice, Marc Gourevitch, Gerald H. Friedland

Research output: Contribution to journalReview article

Abstract

Global access to opioid agonist therapy and HIV/hepatitis C virus (HCV) treatment is expanding but when used concurrently, problematic pharmacokinetic and pharmacodynamic interactions may occur. Articles published from 1966 to 2012 in Medline were reviewed using the following keywords: HIV, AIDS, HIV therapy, HCV, HCV therapy, antiretroviral therapy, highly active antiretroviral therapy, drug interactions, methadone and buprenorphine. In addition, a review of abstracts from national and international meetings and conference proceedings was conducted; selected reports were reviewed as well. The metabolism of both opioid and antiretroviral therapies, description of their known interactions and clinical implications and management of these interactions were reviewed. Important pharmacokinetic and pharmacodynamic drug interactions affecting either methadone or HIV medications have been demonstrated within each class of antiretroviral agents. Drug interactions between methadone, buprenorphine and HIV medications are known and may have important clinical consequences. Clinicians must be alert to these interactions and have a basic knowledge regarding their management.

Original languageEnglish (US)
Pages (from-to)249-269
Number of pages21
JournalExpert Review of Clinical Pharmacology
Volume6
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Practice Management
Hepacivirus
Opioid Analgesics
HIV
Pharmacology
Methadone
Drug Interactions
Buprenorphine
Therapeutics
Pharmacokinetics
Anti-Retroviral Agents
Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome

Keywords

  • antiretroviral therapy
  • buprenorphine
  • drug interactions
  • drug metabolism
  • hepatitis C
  • HIV/AIDS
  • methadone
  • pharmacodynamics
  • pharmacokinetic

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy : Implications and management for clinical practice. / Bruce, R. Douglas; Moody, David E.; Altice, Frederick L.; Gourevitch, Marc; Friedland, Gerald H.

In: Expert Review of Clinical Pharmacology, Vol. 6, No. 3, 05.2013, p. 249-269.

Research output: Contribution to journalReview article

@article{81edb673146d4893ae223cc1b429267a,
title = "A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: Implications and management for clinical practice",
abstract = "Global access to opioid agonist therapy and HIV/hepatitis C virus (HCV) treatment is expanding but when used concurrently, problematic pharmacokinetic and pharmacodynamic interactions may occur. Articles published from 1966 to 2012 in Medline were reviewed using the following keywords: HIV, AIDS, HIV therapy, HCV, HCV therapy, antiretroviral therapy, highly active antiretroviral therapy, drug interactions, methadone and buprenorphine. In addition, a review of abstracts from national and international meetings and conference proceedings was conducted; selected reports were reviewed as well. The metabolism of both opioid and antiretroviral therapies, description of their known interactions and clinical implications and management of these interactions were reviewed. Important pharmacokinetic and pharmacodynamic drug interactions affecting either methadone or HIV medications have been demonstrated within each class of antiretroviral agents. Drug interactions between methadone, buprenorphine and HIV medications are known and may have important clinical consequences. Clinicians must be alert to these interactions and have a basic knowledge regarding their management.",
keywords = "antiretroviral therapy, buprenorphine, drug interactions, drug metabolism, hepatitis C, HIV/AIDS, methadone, pharmacodynamics, pharmacokinetic",
author = "Bruce, {R. Douglas} and Moody, {David E.} and Altice, {Frederick L.} and Marc Gourevitch and Friedland, {Gerald H.}",
year = "2013",
month = "5",
doi = "10.1586/ecp.13.18",
language = "English (US)",
volume = "6",
pages = "249--269",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy

T2 - Implications and management for clinical practice

AU - Bruce, R. Douglas

AU - Moody, David E.

AU - Altice, Frederick L.

AU - Gourevitch, Marc

AU - Friedland, Gerald H.

PY - 2013/5

Y1 - 2013/5

N2 - Global access to opioid agonist therapy and HIV/hepatitis C virus (HCV) treatment is expanding but when used concurrently, problematic pharmacokinetic and pharmacodynamic interactions may occur. Articles published from 1966 to 2012 in Medline were reviewed using the following keywords: HIV, AIDS, HIV therapy, HCV, HCV therapy, antiretroviral therapy, highly active antiretroviral therapy, drug interactions, methadone and buprenorphine. In addition, a review of abstracts from national and international meetings and conference proceedings was conducted; selected reports were reviewed as well. The metabolism of both opioid and antiretroviral therapies, description of their known interactions and clinical implications and management of these interactions were reviewed. Important pharmacokinetic and pharmacodynamic drug interactions affecting either methadone or HIV medications have been demonstrated within each class of antiretroviral agents. Drug interactions between methadone, buprenorphine and HIV medications are known and may have important clinical consequences. Clinicians must be alert to these interactions and have a basic knowledge regarding their management.

AB - Global access to opioid agonist therapy and HIV/hepatitis C virus (HCV) treatment is expanding but when used concurrently, problematic pharmacokinetic and pharmacodynamic interactions may occur. Articles published from 1966 to 2012 in Medline were reviewed using the following keywords: HIV, AIDS, HIV therapy, HCV, HCV therapy, antiretroviral therapy, highly active antiretroviral therapy, drug interactions, methadone and buprenorphine. In addition, a review of abstracts from national and international meetings and conference proceedings was conducted; selected reports were reviewed as well. The metabolism of both opioid and antiretroviral therapies, description of their known interactions and clinical implications and management of these interactions were reviewed. Important pharmacokinetic and pharmacodynamic drug interactions affecting either methadone or HIV medications have been demonstrated within each class of antiretroviral agents. Drug interactions between methadone, buprenorphine and HIV medications are known and may have important clinical consequences. Clinicians must be alert to these interactions and have a basic knowledge regarding their management.

KW - antiretroviral therapy

KW - buprenorphine

KW - drug interactions

KW - drug metabolism

KW - hepatitis C

KW - HIV/AIDS

KW - methadone

KW - pharmacodynamics

KW - pharmacokinetic

UR - http://www.scopus.com/inward/record.url?scp=84877597257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877597257&partnerID=8YFLogxK

U2 - 10.1586/ecp.13.18

DO - 10.1586/ecp.13.18

M3 - Review article

C2 - 23656339

AN - SCOPUS:84877597257

VL - 6

SP - 249

EP - 269

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -